Gastroenterology Research and Practice / 2012 / Article / Tab 3 / Research Article
A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding Table 3 Comparison between the non-high-dose and high-dose PPI before case-controlled matching.
Characteristic Non-high-dose group (
) High-dose group (
)
-valueAge (years)
0.558 Female gender,
(%) 105 (70.0) 44 (62.9) 0.291 Creatinine (mg/dL)
0.018* Hb (g/L)
0.438 Platelet (×109 /L)
0.592 Use of NSAIDs,
(%) 8 (5.3) 6 (8.6) 0.359 Use of aspirin,
(%) 23 (15.3) 9 (12.9) 0.628 Use of clopidogrel,
(%) 15 (10.0) 8 (11.4) 0.747 Use of warfarin,
(%) 5 (3.3) 5 (7.1) 0.206 Coexisting illness,
(%) CKD III, IV/V 47/17 (31.3/11.3) 23/12 (32.9/17.1) 0.422 COPD 8 (5.3) 3 (4.3) 0.740 CAD 21 (14.0) 16 (22.6) 0.102 DM 38 (25.3) 28 (40.0) 0.027* CVA 18 (12.0) 16 (22.9) 0.038* Liver cirrhosis 26 (17.3) 13 (18.6) 0.321 Forrest classification Ia/Ib/IIa/IIb/IIc/III 11/86/12/35/5/1 3/45/7/15/0/0 0.524 Shock on admission 69 (46.0) 43 (61.4) 0.033* Rockall score
0.106 Time to endoscope (hours)
0.107 Hemostasis methods A/B/C/D/E/F 11/86/12/35/5/1 3/45/7/15/0/0 PRBC BT (mL)
0.196 Multiple ulcers,
(%) 50 (38.7) 26 (37.1) 0.580 Rebleeding,
(%) 24 (16.0) 19 (27.1) 0.052 Surgery,
(%) 1 (0.6) 1 (1.4) 0.579 Hospital stay (days)
0.343 Mortality,
(%) 9 (6.0) 8 (11.4) 0.207 Bleeding related/other causes 3/6 1/7
Hb: hemoglobin, NSAID: nonsteroidal anti-inflammatory drug, CKD: chronic kidney disease, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. *
.